Replies to post #6413 on DARA BioSciences, Inc. (DARA)

[Ebuilder]

Maybe this line in the 8K caused some to view this stock as a sell now buy back later play

In addition, the company wishes to identify a strategic partner for the clinical development of KRN5500, currently in Phase 2 for the treatment of chronic, treatment refractory, chemotherapy-induced peripheral neuropathy (CCIPN).